Zacks Investment Research upgraded shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $5.25 price objective on the biopharmaceutical company’s stock.

According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “

Separately, HC Wainwright reissued a buy rating and set a $40.00 price target on shares of ProQR Therapeutics N.V. in a report on Tuesday, June 20th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $14.15.

Shares of ProQR Therapeutics N.V. (PRQR) opened at 4.50 on Tuesday. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The firm’s market cap is $108.47 million. The firm’s 50-day moving average price is $5.03 and its 200 day moving average price is $4.83.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/08/26/proqr-therapeutics-n-v-prqr-raised-to-buy-at-zacks-investment-research.html.

A number of hedge funds have recently added to or reduced their stakes in PRQR. Hikari Power Ltd bought a new stake in ProQR Therapeutics N.V. during the first quarter valued at about $121,000. Redmile Group LLC raised its stake in ProQR Therapeutics N.V. by 2.8% in the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares in the last quarter. Artal Group S.A. raised its stake in ProQR Therapeutics N.V. by 25.0% in the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares in the last quarter. Sphera Funds Management LTD. raised its stake in ProQR Therapeutics N.V. by 65.0% in the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock valued at $1,650,000 after buying an additional 130,000 shares in the last quarter. Finally, Janus Henderson Group PLC bought a new stake in ProQR Therapeutics N.V. during the second quarter valued at about $2,028,000. 35.70% of the stock is owned by institutional investors and hedge funds.

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get a free copy of the Zacks research report on ProQR Therapeutics N.V. (PRQR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for ProQR Therapeutics N.V. (NASDAQ:PRQR)

Receive News & Stock Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related stocks with our FREE daily email newsletter.